NCT05281965 is a EARLY_PHASE1 clinical trial of Retinoic acid in Autism, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

Who is sponsoring NCT05281965?

NCT05281965 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

What drugs are being tested in NCT05281965?

Interventions in NCT05281965: Retinoic acid.

What condition does NCT05281965 study?

NCT05281965 studies Autism, Treatment Adherence, Retinoic Acid, Dup15Q Syndrome.

Is NCT05281965 still recruiting?

NCT05281965 is currently status unknown. Last updated 16 March 2022.

Last reviewed 2022-03-16 · How we verify

NCT05281965

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Clinical Study Evaluating the Efficacy and Safety of Retinoic Acid in Patients With 15q11-q13 Duplication Syndrome

Status unknown EARLY_PHASE1 Last updated 16 March 2022

What this trial tests

EARLY_PHASE1 trial testing Retinoic acid in Autism in 20 participants. Status unknown.

Timeline

1 April 2022

Primary endpoint
1 June 2023

1 June 2024

Quick facts

Lead sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	treatment
Enrollment	20
Start date	1 April 2022
Primary completion	1 June 2023
Estimated completion	1 June 2024
Sites	2 locations across China

Drugs / interventions tested

Retinoic acid — full drug profile →

Conditions studied

Autism — all drugs for Autism →
Treatment Adherence — all drugs for Treatment Adherence →
Retinoic Acid — all drugs for Retinoic Acid →
Dup15Q Syndrome — all drugs for Dup15Q Syndrome →

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

Adults 6 to 18, any sex, with Autism or Treatment Adherence. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Autism Spectrum Disorders (ASD), with its core symptoms of communication and repetitive behaviors, is a serious neurodevelopmental disorder common in childhood and affects about 1% of children. So far, autism remains a clinical dilemma with no effective therapy. The most common chromsomal ability among ASD patients is 15q11-13q duplication syndrome(dup15q syndrome).Clinical phenotypes of dup15q syndrome include autism, mental retardation, epilepsy (usually refractory epilepsy, often manifested as infantile spasm), congenital heart disease, mild facial abnormalities, etc. UBE3A is one of the most important genes in the 15q11-q13 region.Biochemistry and molecular biology of the Chinese Academy of Sciences Hu Ronggui group found a new kind of autism in mechanisms and potential therapeutic targets - describe the ubiquitin ligase UBE3A protein and retinoic acid.Previous studies have shown that the basis of the relevant treatment measures can effectively relieve the mouse model of autism characteristics. Therefore, retinoic acid supplementation in the treatment of dup15q syndrome is a potential therapeutic target.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Retinoic acid

Trials testing the same drug.

NCT04417348 — Opsin Receptors in Melasma · NA · completed
NCT03491267 — Study to Determine Effect of Gentle Wounding to Stimulate Hair Follicle Neogenesis · EARLY_PHASE1 · completed
NCT03392623 — DNA Methylation in Malar Melasma and Its Change by Sunscreen, Retinoic Acid and Niacinamide. · EARLY_PHASE1 · completed

Other recruiting trials for Autism

Currently open trials in the same condition.

NCT07367256 — Using Virtual Reality to Improve Emotion Understanding in Children With Autism · NA · recruiting
NCT06853665 — The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine · Phase 4 · recruiting
NCT06523387 — Online Pivotal Response Treatment Training in Autism Spectrum Disorder · NA · recruiting
NCT07304440 — Adia MED of Winter Park LLC Autism Spectrum Disorder Research Study · Phase 1, PHASE2 · recruiting
NCT07403396 — Static Balance Assessment in Children With ASD Using VRRS · recruiting

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

NCT07445152 — Research on Construction and Verification of Multimodal Medical Imaging Large Model · not yet recruiting
NCT06775665 — A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population · not yet recruiting
NCT07533422 — Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing · NA · not yet recruiting
NCT07487285 — A Non-inferiority Study of Laser Combined With Ultrasonic Debridement Therapy (LCUDT) Versus Manual Combined With Ultras · NA · not yet recruiting
NCT07505186 — Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05281965 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital, School of Medicine, Zhejiang University
Last refreshed: 16 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05281965.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing